Arkansas's Right-to-Try statute notably does not exclude stem cells.
Statute
Ark. Code § 20-15-2101 (2015)
Effective
Effective 2015
Arkansas's Right-to-Try statute permits access to investigational treatments for patients with terminal illness and notably does not carve out an exclusion for stem cell-derived therapies, leaving access available under the standard Right-to-Try framework.
The requirements below are set by Ark. Code § 20-15-2101 (2015). Compliance is the responsibility of each individual treating physician under their state license.
Statutory compliance does not equal FDA approval. The procedures discussed are investigational and have not been approved by the US Food and Drug Administration.
Arkansas has enacted Ark. Code § 20-15-2101 (2015), which sets out specific conditions under which a state-licensed physician may practice in this area. The procedures discussed here are investigational and have not been approved by the US Food and Drug Administration.
No. Adults may travel to Arkansas from any US state for an in-person consultation with a network physician. Whether any procedure is appropriate is a clinical decision determined by the treating physician.
Cost depends on the indication, the cell product, and the treating physician. Each physician sets their own pricing and provides a written estimate. Select Stem Cell does not collect medical fees on behalf of physicians.
Yes. Arkansas law requires the treating physician to provide written disclosure of investigational status and obtain informed consent prior to any procedure.
Continue Reading
We use cookies
We use strictly necessary cookies to make this site work, and (with your permission) functional and analytics cookies to improve your experience. We do not use marketing or behavioral-advertising cookies. Read our Cookie Policy.